137 related articles for article (PubMed ID: 35267013)
21. Older patients with IBD might have higher risk of Parkinson's disease.
Wan QY; Zhao R; Wu XT
Gut; 2020 Jan; 69(1):193-194. PubMed ID: 30518530
[No Abstract] [Full Text] [Related]
22. Which way does the axis tip? IBD increases the risk of Parkinson's disease.
Hutfless S; Wenning GK
Gut; 2019 Jan; 68(1):3. PubMed ID: 29858394
[No Abstract] [Full Text] [Related]
23. Letter: association between COVID-19 and inflammatory bowel disease.
Chen HY; Wang SI; Chang R; Wei JC
Aliment Pharmacol Ther; 2022 May; 55(9):1226-1227. PubMed ID: 35429026
[TBL] [Abstract][Full Text] [Related]
24. Letter to the Editor. Cell therapy for Parkinson's disease.
Schweitzer JS; Herrington TM; Kim KS; Carter BS
J Neurosurg; 2022 Feb; 136(6):1810-1811. PubMed ID: 35120329
[No Abstract] [Full Text] [Related]
25. Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'.
Mantaka A; Tsoukali E; Fragaki M; Karmiris K; Viazis N; Mantzaris GJ; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):300-302. PubMed ID: 33369958
[No Abstract] [Full Text] [Related]
26. 90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors.
Palacios Argueta P; Salazar M; Attar B; Simons-Linares R; Shen B
Inflamm Bowel Dis; 2021 Mar; 27(4):530-537. PubMed ID: 32812037
[TBL] [Abstract][Full Text] [Related]
27. Letter to the Editor: Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study.
Xie H; Zeng D; Chen D; Tang W; Yang Y
Inflamm Bowel Dis; 2020 May; 26(6):e48. PubMed ID: 32195534
[No Abstract] [Full Text] [Related]
28. Letter to the editor-Association between depression and risk of Parkinson's disease in South Korean adults.
Peng H; Lin J; Guan W
J Affect Disord; 2021 Dec; 295():1151-1152. PubMed ID: 34706427
[No Abstract] [Full Text] [Related]
29. A Response to: Letter to the Editor Regarding 'Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'.
Aksan A; Schoepfer A; Juillerat P; Vavricka S; Bettencourt M; Ramirez de Arellano A; Gavata S; Morin N; Valentine WJ; Hunt B
Adv Ther; 2022 Jan; 39(1):815-821. PubMed ID: 34846708
[No Abstract] [Full Text] [Related]
30. Letter to the editor: Triclosan in patients with inflammatory bowel disease.
Peña-Cardelles JF
Med Oral Patol Oral Cir Bucal; 2022 Sep; 27(5):e442-e443. PubMed ID: 35368006
[No Abstract] [Full Text] [Related]
31. Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries.
Camacho-Soto A; Gross A; Searles Nielsen S; Dey N; Racette BA
Parkinsonism Relat Disord; 2018 May; 50():23-28. PubMed ID: 29459115
[TBL] [Abstract][Full Text] [Related]
32. Letter to the Editor Regarding 'Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland'.
Muñoz M; Reinisch W
Adv Ther; 2022 Jan; 39(1):811-814. PubMed ID: 34846707
[No Abstract] [Full Text] [Related]
33. Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
Antar T; Iwaki H; B Singleton A
Mov Disord; 2021 Feb; 36(2):527-528. PubMed ID: 33599005
[No Abstract] [Full Text] [Related]
34. Reply to letter to the editor "Adaptive DBS in Parkinson's disease: Headlines, perspectives and challenges".
Velisar A; Bronte-Stewart H
Brain Stimul; 2019; 12(5):1330-1331. PubMed ID: 31235368
[No Abstract] [Full Text] [Related]
35. Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
Chang HC; Gau SY
Aliment Pharmacol Ther; 2022 Nov; 56(10):1503-1504. PubMed ID: 36271473
[No Abstract] [Full Text] [Related]
36. Letter to the editor regarding "TGM6 variants in Parkinson's disease: clinical findings and functional evidence".
Hall A; Quinn JP; Billingsley KJ
J Integr Neurosci; 2020 Dec; 19(4):735-737. PubMed ID: 33378849
[TBL] [Abstract][Full Text] [Related]
37. Letter to the editor in response to the letter from the EPIPARK Study Group regarding the publication 'Progression of fatigue in Parkinson's disease - a 9-year follow-up' (Eur J Neurol 2021. doi:10.1111/ene.14520).
Ongre SO; Dalen I; Tysnes OB; Alves G; Herlofson K
Eur J Neurol; 2021 Jun; 28(6):e33-e34. PubMed ID: 33547699
[No Abstract] [Full Text] [Related]
38. In reply to the letter to the editor regarding "TGM6 variants in Parkinson's disease: clinical findings and functional evidence".
Chen K; Tan Y; Zhao YX
J Integr Neurosci; 2020 Dec; 19(4):739-740. PubMed ID: 33378850
[TBL] [Abstract][Full Text] [Related]
39. Letter to the Editor regarding "Parkinson's disease and hip fractures: Are complications and mortality rates increased?".
Gallardo-Molina N
Eur J Orthop Surg Traumatol; 2021 Jan; 31(1):199-200. PubMed ID: 32770404
[No Abstract] [Full Text] [Related]
40. Letter to the editor: Parkinson's disease and early subthalamotomy.
Guridi J; Obeso JA
J Neurosurg; 2015 Apr; 122(4):980-1. PubMed ID: 25679280
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
